delpacibart etedesiran   Click here for help

GtoPdb Ligand ID: 14730

Synonyms: AOC 1001 | AOC-1001 | del-desiran
Compound class: Nucleic acid
Comment: Delpacibart etedesiran (AOC 1001) is structurally a monoclonal antibody (mAb)-oligonucleotide conjugate (AOC) in which the mAb binds the transferrin receptor (TFRC;) for targeted delivery of a duplex small interfering RNA (siRNA) payload that degrades the mRNA that encodes DM1 protein kinase (DMPK) [1].

This entry provides information on the siRNA as the component that mediates the agent's intended pharmacodynamic effect. Further details about the parental anti-TFRC mAb are provided in the delpacibart entry. To improve pharmacokinetics and RNA binding the nucleotides in etedesiran are chemically modified (2'-O-methyl/2'-MOE monomers), with a mixed phosphorothioate/phosphate backbone. The mAb is attached to the siRNAs via malemide linkers at Cys-R positions on the passenger strands.

Delpacibart etedesiran is proposed to reduce the global splicing defects that arise from toxic gain-of-function DMPK transcript accummulation in myocytes in myotonic dystrophy type 1.
References
1. Johnson NE, Tai LJ, Hamel JI, Day JW, Statland JM, Soltanzadeh P, Subramony SH, Thornton CA, Arnold WD, Wicklund M et al.. (2026)
An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.
N Engl J Med, 394 (8): 763-772. [PMID:41707138]